1.25T hours with Assessment – Optometry Australia IoE Quality Assurance | 1.25G in New Zealand
The advent of anti-VEGF (vascular endothelial growth factor) therapy has revolutionised the management of retinal diseases over the last decade, particularly for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). In this article commissioned by Bayer Australia Ltd, Dr Jia Hui Lee considers the impact of a new treatment option: aflibercept 8 mg from nAMD and DMO…Read and take test.
